CLSA issued a statement after the issuance of the Most Favored Nation (MFN) Interim Final Rule, and our subsequent legal action we have joined with our partners BIO and Biocom.
CLSA is proud to join with South San Francisco (SSF) life sciences companies and leaders in a campaign to bridge the digital divide for students in the South San Francisco Unified School District (SSFUSD).
This November, voters will have the opportunity to vote yes on Proposition 14 to authorize $5.5 billion in state general obligation bonds to continue the advancement of treatments and cures here in
In September, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule (CMS-3372-P) entitled “Medicare Coverage of Innovative Technology (MCIT) and Definition of ‘Reasonable and Necessary’”.
Produced with PwC US, the 2020 snapshot highlights the strength of California’s biomedical sector – the largest cluster in the world – as evidenced by significant increases in employment, earnings, graduating science and engineering PhDs, VC investment and potential new drugs and medical devices in the pipeline.
The new Fiscal Year (FY) will begin at midnight tonight on October 1st. At the time this update was prepared on September 29th, a government shutdown is unlikely following the House passage of a continuing resolution (CR) to fund the government at FY20 levels through December 11, 2020.
On Friday, September 25th, Governor Newsom signed AB 713 a measure introduced by Assembly member Kevin Mullin (D-South San Francisco).
CLSA is profoundly disappointed by the Administration’s decision to move forward with the flawed concept of a ‘Most Favored Nation’ policy that threatens the innovative life sciences ecosystem and patient access to cutting edge biomedical advancement.
On Wednesday September 9th, the California Supreme Court refused to hear a case brought forward by the Howard Jarvis Taxpayers Association, the California Business Roundtable and the California Business Properties Association regarding whether only a simple majority versus a supermajority vote was necessary to pass a San Francisco corporate tax ballot measure which passed in 2018.
Through this partnership, Catalent Biologics will work closely with CLSA to serve all life sciences companies in California with exceptional service and support for members’ biologic development and manufacturing needs.